BRPI0608176A2 - usos de combinações, combinação e composição farmacêutica para o tratamento de cáncer - Google Patents

usos de combinações, combinação e composição farmacêutica para o tratamento de cáncer

Info

Publication number
BRPI0608176A2
BRPI0608176A2 BRPI0608176-2A BRPI0608176A BRPI0608176A2 BR PI0608176 A2 BRPI0608176 A2 BR PI0608176A2 BR PI0608176 A BRPI0608176 A BR PI0608176A BR PI0608176 A2 BRPI0608176 A2 BR PI0608176A2
Authority
BR
Brazil
Prior art keywords
combination
pharmaceutical composition
cancer treatment
bcr
pharmaceutical compositions
Prior art date
Application number
BRPI0608176-2A
Other languages
English (en)
Inventor
Francis Y F Lee
Roberto Weinmann
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BRPI0608176A2 publication Critical patent/BRPI0608176A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

USOS DE COMBINAçõES, COMBINAçãO E COMPOSIçãO FARMACêUTICA PARA O TRATAMENTO DE CáNCER. A presente invenção refere-se a uma combinação do inibidor de BCR-ABL, exemplificado por 'N-(2-Cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietií)-1 -piperazinil]-2-metil-4-pirimidinil] amino]-5-tiazolcarboxamida e/ou outros inibidores de BCR/ABL e um citotóxico seletivo de células-tronco, exemplificado pelo sal de cloridrato de (R)-2,3,4,5-tetrahidro-1 -(1 H-imidazol-4-ilmetil)-3-(fenil-metil)-4-(2-tienilsulfonil)-1 H-1 ,4-benzodiazepina-7-carbonitrila e/ou outros agentes citotóxicos de células-tronco, composições farmacêuticas da combinação a aos processos de utilização das composições farmacêuticas no tratamento de distúrbios oncológicos.
BRPI0608176-2A 2005-04-13 2006-04-13 usos de combinações, combinação e composição farmacêutica para o tratamento de cáncer BRPI0608176A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US67074405P 2005-04-13 2005-04-13
US74843305P 2005-12-08 2005-12-08
US11/402,502 US20060235006A1 (en) 2005-04-13 2006-04-12 Combinations, methods and compositions for treating cancer
PCT/US2006/013773 WO2006113304A2 (en) 2005-04-13 2006-04-13 Combinations, methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
BRPI0608176A2 true BRPI0608176A2 (pt) 2009-11-17

Family

ID=37109315

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0608176-2A BRPI0608176A2 (pt) 2005-04-13 2006-04-13 usos de combinações, combinação e composição farmacêutica para o tratamento de cáncer

Country Status (12)

Country Link
US (2) US20060235006A1 (pt)
EP (1) EP1868435A4 (pt)
JP (1) JP2008536853A (pt)
KR (1) KR20080004495A (pt)
AU (1) AU2006236812A1 (pt)
BR (1) BRPI0608176A2 (pt)
CA (1) CA2604581A1 (pt)
EA (1) EA200702238A1 (pt)
MX (1) MX2007012537A (pt)
NO (1) NO20075087L (pt)
TW (1) TW200722091A (pt)
WO (1) WO2006113304A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2260592C9 (ru) * 1999-04-15 2017-04-07 Бристол-Маерс Сквибб Ко. Циклические ингибиторы протеинтирозинкиназ
AU2006210572B2 (en) 2005-02-03 2011-08-04 The General Hospital Corporation Method for treating gefitinib resistant cancer
CA2610157A1 (en) * 2005-06-09 2006-12-21 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant kit protein
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
US20090099197A1 (en) * 2005-11-15 2009-04-16 Bristol-Myers Squibb Company Methods of Identifying and Treating Individuals Exhibiting MDR-1 Overexpression With Protein Tyrosine Kinase Inhibitors and Combinations Thereof
RU2452492C2 (ru) * 2006-04-05 2012-06-10 Новартис Аг КОМБИНАЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОРЫ Bcr-Abl/c-Kit/PDGF-R TK, ДЛЯ ЛЕЧЕНИЯ РАКА
BRPI0710675A2 (pt) * 2006-04-07 2011-08-23 Novartis Ag uso de inibidores de c-src em combinação com um composto pirimidilaminobenzamida para o tratamento de leucemia
WO2008064004A2 (en) * 2006-11-16 2008-05-29 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
US20080119463A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
WO2008089135A2 (en) * 2007-01-12 2008-07-24 University Of South Florida Identification of biomarkers predictive of dasatinib effects in cancer cells
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US8338425B2 (en) * 2007-12-10 2012-12-25 Concert Pharmaceuticals, Inc. Heterocyclic kinase inhibitors
CA2725598C (en) 2008-06-17 2013-10-08 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
US8119129B2 (en) 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
WO2010017163A1 (en) * 2008-08-04 2010-02-11 Wyeth Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
US20100233172A1 (en) * 2008-12-16 2010-09-16 Bristol-Myers Squibb Company Methods of inhibiting quiescent tumor proliferation
SI2769737T1 (sl) * 2009-07-20 2017-06-30 Bristol-Myers Squibb Company Kombinacija anti-ctla4 protitelesa z etoposidom za sinergistično zdravljenje proliferativnih bolezni
EP2470212A4 (en) * 2009-10-01 2013-12-04 Csl Ltd METHOD FOR TREATING POSITIVE PHILADELPHIA CHROMOSOME LEUKEMIA

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
RU2260592C9 (ru) * 1999-04-15 2017-04-07 Бристол-Маерс Сквибб Ко. Циклические ингибиторы протеинтирозинкиназ
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
CZ299756B6 (cs) * 2001-05-16 2008-11-12 Novartis Ag Kombinace s obsahem N-{5-[4-(4-methyl-piperazino-methyl)benzoylamido]-2-methylfenyl}-4-(3-pyridyl)-2-pyrimidin-aminu k lécení proliferativních onemocnení
AU2003259717A1 (en) * 2002-08-07 2004-02-25 Bristol-Myers Squibb Company Modulators of rabggt and methods of use thereof
US20050009891A1 (en) * 2003-07-09 2005-01-13 Lee Francis Y. Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
PE20051096A1 (es) * 2004-02-04 2006-01-23 Novartis Ag Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida
US7491725B2 (en) * 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
TW200628156A (en) * 2004-11-04 2006-08-16 Bristol Myers Squibb Co Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases

Also Published As

Publication number Publication date
EP1868435A4 (en) 2009-04-01
WO2006113304A3 (en) 2007-08-02
JP2008536853A (ja) 2008-09-11
TW200722091A (en) 2007-06-16
EA200702238A1 (ru) 2008-04-28
AU2006236812A1 (en) 2006-10-26
WO2006113304A2 (en) 2006-10-26
KR20080004495A (ko) 2008-01-09
MX2007012537A (es) 2007-12-10
EP1868435A2 (en) 2007-12-26
NO20075087L (no) 2008-01-09
CA2604581A1 (en) 2006-10-26
US20090054415A1 (en) 2009-02-26
US20060235006A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
BRPI0608176A2 (pt) usos de combinações, combinação e composição farmacêutica para o tratamento de cáncer
NO20075154L (no) Formuleringer av en src/abl-inhibitor
AR112118A2 (es) Inhibidores de pi-3 quinasa
PE20061394A1 (es) Metabolitos de n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamidas
NO20084923L (no) N-(2-thiazolyl)-amid derivater som GSK-3 inhibitorer
DK1776349T3 (da) 2-amino-puinazolin derivater anvendelige som inhibitorer af beta-sekretase (BACE)
NO20081569L (no) Administrasjon av dipeptidylpeptildaseinhibitorer
PL406680A1 (pl) Inhibitory kinaz tyrozynowych
ATE396731T1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
NO20081963L (no) Fremgangsmate for behandling
CL2008002354A1 (es) Forma cristalina de la sal diclorhidrato de ((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1h-imidazol-5-il)-4-bifenilil)-1h-imidazol-2-il)-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo; composición y combinacion farmacéutica; y su uso para tratar la hepatitis c.
AP1545A (en) Hydrochloride salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione.
NO20084418L (no) Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
BRPI0517435A (pt) triazóis úteis como inibidores de proteìna cinase
ATE522526T1 (de) 4-(3-(2-(phenyl)morpholino)-2-oxopyrrolidin-1-y )-n-(thiazol-2-yl)benzolsulfonamidderivate und verwandte verbindungen als ionenkanalmodulatoren zur behandlung von schmerzen
ATE497961T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
BRPI0516200A (pt) forma cristalina do cloridrato de (3-ciano-1h-indol-7-il)-[4-(4-fluorfenetril)piperazin-1-i l]metanona
WO2007116025A3 (en) Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
ECSP077845A (es) Composiciones y sales dermatológicas para el tratamiento de enfermedades dermatológicas
NO20084190L (no) Anvendelse av VX-702 til behandling av revmatoid artritt
EA200970239A1 (ru) Режим титрования бифепрунокса для лечения шизофрении и наборы для применения в этой области
WO2007063384A3 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
PE20030277A1 (es) Composicion farmaceutica que comprende 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y l-dopa
AR051213A1 (es) 1-(2-(4-bencil-4-hidroxi-piperidin-1-il)-etil)-3-(2-metil-quinolin-4-il)-urea como una sal sulfato cristalina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.